All In Biotech

Drug Trial Radar · NCT06709612

Postsurgical Analgesia After Hernia Repair

Pilot Phase II Study of AMT-143 for Postsurgical Analgesia After Hernia Repair

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 27, 2025

Primary completion

Mar 2026

Study completion May 2026

Sponsor

Lead sponsor
AmacaThera Inc.Industry
Sponsor type
Industry
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of three ascending doses of AMT-143 to determine the appropriate dose of AMT-143 for the management of postsurgical pain following inguinal hernia repair.

Conditions

  • Hernia Repair
  • Hernia Inguinal
  • Hernia Surgery
  • Hernia, Inguinal/Surgery
  • Hernia, Inguinal

Interventions

  • AMT-143Drug

    AMT-143 is provided as a hydrogel containing 385 mg/mL ropivacaine (on a ropivacaine hydrochloride equivalence basis). Participants undergoing primary open hernia repair, will be randomized to one of three treatment cohorts of escalating doses of AMT-143 hydrogel: * Cohort 1: 1 mL AMT-143 hydrogel * Cohort 2: 2 mL AMT-143 hydrogel * Cohort 3: 3 mL AMT-143 hydrogel

  • Saline (NaCl 0,9 %) (placebo)Other

    Saline placebo will consist of 0.9% sodium chloride injection USP and will be administered in an amount matching the volume of AMT-143 to be used in each of the Cohorts 1 to 3.

  • ropivacaineDrug

    The active comparator, ropivacaine hydrochloride 1% solution will be administered at a volume of 5 mL (50 mg) for all 3 cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events to evaluate the safety and tolerability of AMT-143Time frame: From surgery to Day 28 follow-up
  2. Pharmacokinetics of AMT-143Time frame: From surgery to Day 28 follow-up

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.